| ID | 1334 |
| Name of the vaccine | CVD 908 |
| Microbe | Bacteria |
| Disease name | Typhoid |
| Name of bacteria | Salmonella typhi |
| Type of vaccine | Live attenuated |
| Nucleic acid content | DNA |
| Age | NA |
| Description of the vaccine | Attenuation of Salmonella enterica serovar Typhi by deletions in the aroC gene. |
| Name of the manufacturer | Centre for Vaccine Development, University of Maryland |
| Name of the manufacturing country | NA |
| Year of manufacture | NA |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram negative bacteria |
| Efficacy | NA |
| Vaccine formulation | Oral dose |
| Dosage | Single oral dose. |
| Mechanism of action | Serum IgG anti–lipopolysaccharide (LPS) antibodies and IgA anti-LPS antibody-secreting cells (ASCs). |
| Route of administration | Oral |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | NA |
| Post vaccination | NA |
| Dose type | Single dose |
| Interspecies transfer | NA |
| PubMed identifier | 17582563 |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=249&keywords= |
| Other name | NA |
| Additional Links | NA
|